MDT Stock Overview
Develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
My Notes
Capture your thoughts, links and company narrative
Medtronic plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$88.08 |
| 52 Week High | US$92.68 |
| 52 Week Low | US$75.96 |
| Beta | 0.84 |
| 1 Month Change | 8.70% |
| 3 Month Change | -4.54% |
| 1 Year Change | 2.02% |
| 3 Year Change | -15.45% |
| 5 Year Change | -26.10% |
| Change since IPO | 60,433.17% |
Recent News & Updates
We Think Medtronic (NYSE:MDT) Can Stay On Top Of Its Debt
Jan 20
Medtronic: A Dividend Aristocrat That's Poised To Pop
Jan 06Investors Appear Satisfied With Medtronic plc's (NYSE:MDT) Prospects
Jan 06Medtronic Stock Is Still A Great "Buy"
Dec 26Recent updates
We Think Medtronic (NYSE:MDT) Can Stay On Top Of Its Debt
Jan 20Medtronic: A Dividend Aristocrat That's Poised To Pop
Jan 06Investors Appear Satisfied With Medtronic plc's (NYSE:MDT) Prospects
Jan 06Medtronic Stock Is Still A Great "Buy"
Dec 26Medtronic (NYSE:MDT) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Dec 03Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing
Nov 19Medtronic (NYSE:MDT) Hasn't Managed To Accelerate Its Returns
Nov 08Medtronic: Undervalued But Trapped In Slow Growth (Rating Downgrade)
Oct 31Is It Time To Consider Buying Medtronic plc (NYSE:MDT)?
Oct 13Medtronic: Undervalued Dividend Aristocrat With High Margins
Oct 10An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 33% Undervalued
Sep 30Medtronic (NYSE:MDT) Boosts FY 2025 Guidance Amid Strong Q1 Earnings and Strategic Share Buybacks
Sep 16Medtronic: An Undervalued Stock With Durable Competitive Advantages
Sep 16Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Sep 05Medtronic: Is The Company Back?
Aug 26Medtronic: Still A Buy Before Earnings
Aug 17Returns At Medtronic (NYSE:MDT) Appear To Be Weighed Down
Aug 08Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential
Jul 16At US$77.06, Is Medtronic plc (NYSE:MDT) Worth Looking At Closely?
Jul 11Medtronic (NYSE:MDT) Is Paying Out A Larger Dividend Than Last Year
Jun 27Medtronic: Why I Disagree With The Crowd
Jun 14Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's
Jun 10Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued
May 27Medtronic (NYSE:MDT) Has Announced That It Will Be Increasing Its Dividend To $0.70
May 26These 4 Measures Indicate That Medtronic (NYSE:MDT) Is Using Debt Reasonably Well
May 22Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release
May 13Is Medtronic plc (NYSE:MDT) Trading At A 20% Discount?
May 0135% Undervalued? Medtronic's Future Looks Very Bright
Apr 12Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now
Mar 27Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth
Mar 11Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69
Mar 11Medtronic: Its Recent Beat Proves That It Continues To Be A Rock
Feb 25Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 22Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility
Feb 16A Look At The Fair Value Of Medtronic plc (NYSE:MDT)
Jan 31Medtronic Stock's Rally Is Set To Continue
Jan 11Medtronic: The GLP-1 Drug Headwinds Are Overblown
Dec 103.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic
Nov 28Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings
Nov 17Medtronic Faces Potential Decline Despite Financial Strength
Oct 29Shareholder Returns
| MDT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.3% | 3.9% | 3.1% |
| 1Y | 2.0% | 12.0% | 23.7% |
Return vs Industry: MDT underperformed the US Medical Equipment industry which returned 12% over the past year.
Return vs Market: MDT underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| MDT volatility | |
|---|---|
| MDT Average Weekly Movement | 2.9% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MDT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MDT's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 95,000 | Geoff Martha | www.medtronic.com |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.
Medtronic plc Fundamentals Summary
| MDT fundamental statistics | |
|---|---|
| Market cap | US$112.94b |
| Earnings (TTM) | US$4.29b |
| Revenue (TTM) | US$33.00b |
26.3x
P/E Ratio3.4x
P/S RatioIs MDT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDT income statement (TTM) | |
|---|---|
| Revenue | US$33.00b |
| Cost of Revenue | US$11.42b |
| Gross Profit | US$21.58b |
| Other Expenses | US$17.29b |
| Earnings | US$4.29b |
Last Reported Earnings
Oct 25, 2024
Next Earnings Date
Feb 18, 2025
| Earnings per share (EPS) | 3.34 |
| Gross Margin | 65.40% |
| Net Profit Margin | 13.00% |
| Debt/Equity Ratio | 58.0% |
How did MDT perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yield85%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 06:48 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/10/25 |
| Annual Earnings | 2024/04/26 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medtronic plc is covered by 64 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kadambari Daptardar | Accountability Research Corporation |
| Harshit Gupta | Accountability Research Corporation |
| David Toung | Argus Research Company |